Last reviewed · How we verify
NCT05820451
Impella Real-World Surveillance of Patients Using Sodium Bicarbonate
trial testing Impella CP, 2.5, 5.0 and 5.5 with Sodium Bicarbonate used as purge solution in Cardiogenic Shock in 312 participants. Completed in 22 February 2024.
22 February 2024
Quick facts
| Lead sponsor | Abiomed Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 312 |
| Start date | 15 December 2022 |
| Primary completion | 22 February 2024 |
| Estimated completion | 22 February 2024 |
| Sites | 20 locations across United States |
Drugs / interventions tested
- Impella CP, 2.5, 5.0 and 5.5 with Sodium Bicarbonate used as purge solution
- Impella RP with Sodium Bicarbonate used as purge solution
Conditions studied
- Cardiogenic Shock — all drugs for Cardiogenic Shock →
- High Risk PCI — all drugs for High Risk PCI →
Sponsor
Abiomed Inc. — full company profile →
Who can join
Eligibility, any sex, with Cardiogenic Shock or High Risk PCI. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The population enrolled in this study are all subjects who received an Impella in which a bicarbonate-based purge solution was used.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05820451
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiogenic Shock
Currently open trials in the same condition.
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07345559 — Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock · NA · recruiting
- NCT07374289 — On Scene ECPR in Ostrava · NA · recruiting
- NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
- NCT07309029 — Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR · recruiting
Other Abiomed Inc. trials
Trials by the same sponsor.
- NCT06965504 — INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for C · NA · not yet recruiting
- NCT06765226 — Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps · recruiting
- NCT06964685 — Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock · recruiting
- NCT06308055 — Abiomed Impella RT-DAQ - Observational Study · active not recruiting
- NCT06637644 — Impella RP Flex with Smart Assist · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05820451 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abiomed Inc.
- Last refreshed: 4 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05820451.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing